Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved ...

Vertex Pharmaceuticals (VRTX) stock is in focus as the FDA greenlights label expansions for its cystic fibrosis drugs, ...

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of ...

The cost of a popular Vertex Pharmaceuticals therapy could be contributing to cystic fibrosis (CF) treatment disparities around the world, researchers argued in a recent paper. Just 12% of some ...

- For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease– -12,000 people with one ...

BUFFALO, N.Y. — Nicole Ellis completed her first 5k run in 2020, something that just a short time ago would've seemed almost impossible. "I am currently healthier than I have been in the last ten ...

COLORADO (KCNC) — Some Coloradans are sounding an alarm after learning a state board is considering capping the price of a life-saving drug. They’re worried the move could cause the manufacturer to ...

Vertex Pharmaceuticals Inc. VRTX announced that the FDA has accepted its supplemental new drug application (sNDA) for the label expansion of its triple combination ...

No one disputes the therapeutic value of Vertex Pharmaceuticals’ triplet drug Trikafta for cystic fibrosis—not even the cost watchdogs at the Institute for Clinical and Economic Review (ICER). But ...

Associate Health Minister David Seymour welcomes Pharmac’s decision to fund Trikafta and Alyftrek for children with cystic fibrosis, regardless of their age from 1 April 2026. Beginning tomorrow ...

It's currently only funded for those aged six and older.

Regan Sparks, who has cystic fibrosis, takes medication that means she is not eligible for a visa.